68-5
63/120

Takayuki UCHIDA, Motomi NASU, Takashi HASHIMOTO, Masahiko TSURUMARU, Yoshiaki KAJIYAMAObjectives: Some previous studies reported that the levels of a low-density lipoprotein receptor relative with 11 ligand-binding repeats (LR11) was a prognostic marker in some malignant tumors; however, whether LR11 is related to survival in patients with esophageal cancer remains unclear.Methods: In this study, we measured LR11 in the preoperative serum of 46 patients of esophageal cancer who undergoing surgery using a sandwich enzyme-linked immunosorbent assay (ELISA) method with anti-LR11 monoclonal antibodies. We investigated the correlation between the level of LR11 and survival of patients with esophageal cancer. Clinicopathological data were retrospectively retrieved from our institution’s database.Results: The patients were divided into two groups (low LR11 and high LR11) based on the level of LR11. There was no statistical difference in clinicopathological factors between these two groups. The low LR11 group had a significantly longer overall survival than the high LR11 group.Conclusions: LR11 can be measured with a relatively simple ELISA and is potentially a new prognostic marker for esophageal cancer.Key words: esophageal cancer, lipoprotein receptor, LR11, biomarkerJuntendo Medical Journal2022. 68(5), 513-520Original ArticlesExamination of a Low-density Lipoprotein Receptor Relative with 11 Ligand-binding Repeats (LR11) as a Biomarker in Esophageal CancerIntroductionEleven ligand-binding repeats (LR11) is a receptor that shares a gene structure with the low-density lipoprotein (LDL) receptor and serves as an essen-tial lipoprotein receptor that regulates the homeo-stasis of cholesterol metabolism. LDL receptors are thought to be involved in arteriosclerosis as well as in the migration of vascular smooth muscle cells1). It has been reported that the expression of the lipo-protein receptor related protein-1 or the LDL receptor-related protein 1B is an expression of a function-deficient gene family2, 3). This gene family was identified from lung cancer and may be involved Department of Esophageal & Gastroenterological Surgery, Juntendo University Graduate School of Medicine, Tokyo, JapanCorresponding author: Motomi Nasu Department of Esophageal & Gastroenterological Surgery, Juntendo University Graduate School of Medicine2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, JapanTEL: +81-3-3813-3111 FAX: +81-3-5802-1951 E-mail: mnasu@juntendo.ac.jp〔Received Feb. 22, 2022〕〔Accepted Jul. 19, 2022〕J-STAGE Advance published date: Oct. 4, 2022Copyright © 2022 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited. doi: 10.14789/jmj.JMJ22-0008-OAin the infiltration of tumor cells or metastasis2, 3). LR11, which is part of the LDL receptor family, has been reported as a marker for Alzheimer’s disease and arteriosclerosis4), as well as for leukemia5), and it has been reported that it may also be expressed in the serum of patients with cancer. However, there is no study for association between LR11 and esophageal cancer. In this study, we examined the relationship between preoperatively collected serum LR11 levels in patients with thoracic esophageal cancer and survival to clarify whether LR11 is a useful prognostic factor for esophageal cancer.513

元のページ  ../index.html#63

このブックを見る